Theoretical strategy for choosing piggyback intraocular lens powers in young children

Predictability of Intraocular Lens Calculation and Early Refractive Status

“…Eye growth occurs rapidly in the first 6 months of life, so that increases in axial length during the first month after surgery could result in a reduction in the amount of hyperopia measured. Based on a hybrid logarithmic model of typical refractive growth, 21 a typical eye made pseudophakic at age 1 month with a postoperative refraction of +8.0 D will have a myopic shift of 0.7 D by the age of 2 months, and a typical eye made pseudophakic at age 5 month with a postoperative refraction of +6.0 D will have a myopic shift of 0.4 D by the age of 6 months. Refraction was deferred until the one month visit to allow for resolution of the potentially large astigmatic error that can be induced by sutures in infant eyes, or changes induced by inflammation or corneal edema.…”

Assessment of a single-piece hydrophilic acrylic IOL for piggyback sulcus fixation in pseudophakic cadaver eyes

“…In addition to secondary piggyback implantation to correct postoperative ametropia or to provide multifocality in an eye with previous implantation of a monofocal IOL, primary implantation of the Sulcoflex IOL can be performed to manage, for example, refractive changes in pediatric eyes. 22,23 The surgical trauma associated with Sulcoflex IOL implantation is significantly less than that occurring after explantation/exchange of an in-the-bag IOL, especially after a long-term postoperative period. Therefore, we believe the concept of the Sulcoflex as a supplementary IOL is attractive and deserves further study.…”

Temporary Piggyback Intraocular Lens Implantation Versus Single Intraocular Lens Implantation in Congenital Cataracts: Long-Term Clinical Outcomes

“…The power of the temporary IOL was set to approximately 20% to 30% of the total IOL power. 10,16 Postoperatively, topical 0.3% tobramycin (Tobrex; Alcon, Fort Worth, TX, USA) and topical 1% prednisolone acetate eye drops (Pred Forte; Allergan, Irvine, CA, USA) were administered in all patients four times a day for approximately 4 weeks. Topical 2% homatropine (Isopto Homatropine; Alcon) was also administered twice a day for 2 weeks.…”